Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Tristetraprolin (ZFP36) and TIS11B (ZFP36-L1)

  • Nadia Cherradi
  • Jean-Jacques Feige
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101947

Synonyms

Historical Background

The characterization of the tristetraprolin (TTP) family of RNA-binding proteins started in the early 1990s when Harvey Herschmann first cloned an immediate-early response gene induced by the carcinogenic phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) that he named TIS-11, standing for TPA-induced sequence 11 (Varnum et al. 1989). This and concurrent teams rapidly established...

This is a preview of subscription content, log in to check access.

References

  1. Baou M, Jewell A, Murphy JJ. TIS11 family proteins and their roles in posttranscriptional gene regulation. J Biomed Biotechnol. 2009;2009:634520.  https://doi.org/10.1155/2009/634520.CrossRefPubMedPubMedCentralGoogle Scholar
  2. Bell SE, Sanchez MJ, Spasic-Boskovic O, Santalucia T, Gambardella L, Burton GJ, et al. The RNA binding protein Zfp36l1 is required for normal vascularisation and post-transcriptionally regulates VEGF expression. Dev Dyn. 2006;235:3144–55.PubMedPubMedCentralCrossRefGoogle Scholar
  3. Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science. 1998;281:1001–5.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Carrick DM, Chulada P, Donn R, Fabris M, McNicholl J, Whitworth W, et al. Genetic variations in ZFP36 and their possible relationship to autoimmune diseases. J Autoimmun. 2006;26:182–96.  https://doi.org/10.1016/j.jaut.2006.01.004.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Ciais D, Cherradi N, Bailly S, Grenier E, Berra E, Pouyssegur J, et al. Destabilization of vascular endothelial growth factor mRNA by the zinc-finger protein TIS11b. Oncogene. 2004;23:8673–80.  https://doi.org/10.1038/sj.onc.1207939.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Ciais D, Cherradi N, Feige JJ. Multiple functions of tristetraprolin/TIS11 RNA-binding proteins in the regulation of mRNA biogenesis and degradation. Cell Mol Life Sci. 2013;70:2031–44.  https://doi.org/10.1007/s00018-012-1150-y.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Essafi-Benkhadir K, Onesto C, Stebe E, Moroni C, Pages G. Tristetraprolin inhibits Ras-dependent tumor vascularization by inducing vascular endothelial growth factor mRNA degradation. Mol Biol Cell. 2007;18:4648–58.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Fabian MR, Frank F, Rouya C, Siddiqui N, Lai WS, Karetnikov A, et al. Structural basis for the recruitment of the human CCR4-NOT deadenylase complex by tristetraprolin. Nat Struct Mol Biol. 2013;20:735–9.  https://doi.org/10.1038/nsmb.2572.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Griseri P, Bourcier C, Hieblot C, Essafi-Benkhadir K, Chamorey E, Touriol C, et al. A synonymous polymorphism of the Tristetraprolin (TTP) gene, an AU-rich mRNA-binding protein, affects translation efficiency and response to Herceptin treatment in breast cancer patients. Hum Mol Genet. 2011;20:4556–68.  https://doi.org/10.1093/hmg/ddr390.CrossRefPubMedPubMedCentralGoogle Scholar
  10. Lai WS, Stumpo DJ, Blackshear PJ. Rapid insulin-stimulated accumulation of an mRNA encoding a proline-rich protein. J Biol Chem. 1990;265:16556–63.PubMedPubMedCentralGoogle Scholar
  11. Patial S, Curtis 2nd AD, Lai WS, Stumpo DJ, Hill GD, Flake GP, et al. Enhanced stability of tristetraprolin mRNA protects mice against immune-mediated inflammatory pathologies. Proc Natl Acad Sci USA. 2016;113:1865–70.  https://doi.org/10.1073/pnas.1519906113.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Planel S, Rataj F, Feige J-J, Cherradi N. Post-transcriptional regulation of angiogenesis through AU-rich mRNA degradation: potential application in cancer therapy. In: Feige J-J, Pagès G, Soncin F, editors. Molecular mechanisms of angiogenesis: from ontogenesis to oncogenesis. Paris: Springer; 2014. p. 353–72.CrossRefGoogle Scholar
  13. Planel S, Salomon A, Jalinot P, Feige J, Cherradi N. A novel concept in antiangiogenic and antitumoral therapy: multitarget destabilization of short-lived mRNAs by the zinc finger protein ZFP36L1. Oncogene. 2010;29:5989–6003.PubMedPubMedCentralCrossRefGoogle Scholar
  14. Rataj F, Planel S, Desroches-Castan A, Le Douce J, Lamribet K, Denis J, et al. The cAMP pathway regulates mRNA decay through phosphorylation of the RNA-Binding Protein TIS11b/BRF1. Mol Biol Cell. 2016.  https://doi.org/10.1091/mbc.E16-06-0379.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Sanduja S, Blanco FF, Dixon DA. The roles of TTP and BRF proteins in regulated mRNA decay. Wiley Interdiscip Rev RNA. 2011;2:42–57.  https://doi.org/10.1002/wrna.28.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Sanduja S, Blanco FF, Young LE, Kaza V, Dixon DA. The role of tristetraprolin in cancer and inflammation. Front Biosci. 2012;17:174–88.CrossRefPubMedCentralGoogle Scholar
  17. Sedlyarov V, Fallmann J, Ebner F, Huemer J, Sneezum L, Ivin M, et al. Tristetraprolin binding site atlas in the macrophage transcriptome reveals a switch for inflammation resolution. Mol Syst Biol. 2016;12:868.  https://doi.org/10.15252/msb.20156628.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Stumpo DJ, Byrd NA, Phillips RS, Ghosh S, Maronpot RR, Castranio T, et al. Chorioallantoic fusion defects and embryonic lethality resulting from disruption of Zfp36L1, a gene encoding a CCCH tandem zinc finger protein of the tristetraprolin family. Mol Cell Biol. 2004;24:6445–55.PubMedPubMedCentralCrossRefGoogle Scholar
  19. Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD, et al. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity. 1996;4:445–54.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Varnum BC, Lim RW, Sukhatme VP, Herschman HR. Nucleotide sequence of a cDNA encoding TIS11, a message induced in Swiss 3 T3 cells by the tumor promoter tetradecanoyl phorbol acetate. Oncogene. 1989;4:119–20.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Institut National de la Santé et de la Recherche Médicale Unité 1036GrenobleFrance
  2. 2.CEA, Biosciences and Biotechnology Institute of Grenoble, Laboratory Biology of Cancer and InfectionGrenobleFrance
  3. 3.University Grenoble-AlpesGrenobleFrance